Crescent Biopharma Appoints David Lubner to Board of Directors

Core Insights - Crescent Biopharma, Inc. has appointed David Lubner to its board of directors, bringing 30 years of experience in finance, operations, and corporate strategy [1][2] - The company is focused on developing precision-engineered molecules for solid tumors, with its lead program, CR-001, a tetravalent PD-1 x VEGF bispecific antibody, expected to submit an Investigational New Drug (IND) application in Q4 2025 [3][4] - Crescent's acquisition agreement with GlycoMimetics, Inc. is anticipated to close in Q2 2025, allowing the combined entity to advance Crescent's portfolio under the name Crescent Biopharma [3][4] Company Overview - Crescent Biopharma is a biotechnology company dedicated to advancing care for patients with solid tumors through novel precision-engineered molecules [4] - The company's pipeline includes three programs, with CR-001 as the lead, alongside CR-002 and CR-003, which are antibody-drug conjugates targeting undisclosed mechanisms [4] Leadership and Expertise - David Lubner's previous roles include CFO positions at Ra Pharmaceuticals, Tetraphase Pharmaceuticals, and PharMetrics, contributing significant expertise to Crescent's strategic direction [2] - Lubner is also involved with several other biotechnology companies, enhancing Crescent's network and potential for collaboration [2]